Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?

被引：2
|
作者：
Owen, Dwight H.
Otterson, Gregory A.
机构：
[1] Ohio State Univ, Wexner Med Ctr, Div Med Oncol, Columbus, OH 43210 USA
[2] James Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
CELL LUNG-CANCER; NIVOLUMAB; PNEUMONITIS; DOCETAXEL; PROFILE; PEMBROLIZUMAB; CHEMOTHERAPY;
D O I：
10.21037/jtd.2018.09.102
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S4069 / S4072
页数：4
相关论文
共 50 条
  • [1] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    [J]. ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [2] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
    Yu Wei-Bo
    Rao Jian-Yu
    [J]. 慢性疾病与转化医学(英文), 2019, 5 (03) : 170 - 177
  • [3] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns
    Nishino, Mizuki
    Hatabu, Hiroto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14)
  • [4] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    [J]. UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [5] Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege
    Cheng, Xuyang
    Dai, Hehua
    Wan, Ni
    Moore, Yolonda
    Vankayalapati, Ramakrishna
    Dai, Zhenhua
    [J]. TRANSPLANTATION, 2009, 87 (12) : 1778 - 1786
  • [6] Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
    Zhang, Ni
    Tu, Jingyao
    Wang, Xue
    Chu, Qian
    [J]. IMMUNOTHERAPY, 2019, 11 (05) : 429 - 441
  • [7] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns Reply
    Naidoo, Jarushka
    Iyriboz, Tunc
    Cunningham, Jane
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1629 - +
  • [8] Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
    Robert, Caroline
    Soria, Jean-Charles
    Eggermont, Alexander M. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2968 - 2971
  • [9] OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A386 - A387
  • [10] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
    Liu, Xiaojun
    Yang, Zhongxia
    Latchoumanin, Olivier
    Qiao, Liang
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860
12345